Stay updated on Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page.

Latest updates to the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedNo additions or deletions were provided. The page content about the study details remains unchanged.SummaryDifference0.1%

- Check15 days agoChange DetectedThe page revision label was updated from v3.6.2 to v3.6.3, indicating a minor metadata update to the page.SummaryDifference0.1%

- Check23 days agoChange DetectedThe page revision was updated from v3.6.0 to v3.6.2, indicating a maintenance update to the ClinicalTrials.gov record. This reflects behind-the-scenes fixes or tweaks and does not alter the study details presented to users.SummaryDifference0.1%

- Check37 days agoChange DetectedThe study record now indicates termination due to poor accrual and includes the note 'No longer looking for participants.' Navigation/help items were added (How to Read a Study Record, Common Questions, How to Join a Study), and the revision label was updated to v3.6.0 with a heading adjustment for Intervention/Treatment.SummaryDifference0.6%

- Check44 days agoChange DetectedFooter revision updated from v3.5.4 to v3.5.5, indicating a new version of the page. No substantive content, including the study details or eligibility criteria, was changed.SummaryDifference0.1%

- Check66 days agoChange DetectedThe page revision tag was updated from v3.5.3 to v3.5.4, signaling a new release of the page content.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page.